|
Patent landscape, scope, and claims: |
Patent Analysis of United States Patent 8,338,639
What is the scope of Patent 8,338,639?
Patent 8,338,639 covers a specific class of pharmaceutical compounds designed for modulating G protein-coupled receptor (GPCR) activity. The patent primarily claims:
- Novel chemical entities with structures characterized by a core scaffold with specific substitutions.
- Methods for synthesizing these compounds.
- Pharmaceutical compositions containing the compounds.
- Therapeutic uses in treating diseases linked to GPCR activity, including neurological disorders, metabolic syndromes, and cardiovascular diseases.
Key Structural Elements:
- A central aromatic ring system substituted at particular positions.
- Flexible linker groups enabling receptor binding.
- Optional functional groups that influence pharmacokinetic properties.
The patent explicitly prohibits use outside of these defined chemical structures and their pharmaceutically acceptable salts or prodrugs.
What are the main claims of Patent 8,338,639?
The patent's claims are structured in multiple categories:
Composition Claims
- Claim 1: A pharmaceutical composition comprising at least one compound represented by the chemical formula outlined in the patent, along with a pharmaceutically acceptable carrier.
- Claim 2: The composition of claim 1, wherein the compound is a salt, hydrate, or prodrug.
Compound Claims
- Claim 3: A compound with a structure having the formula [detailed chemical structure].
- Claim 4: Variations where X, Y, Z positions are substituted with specific groups (e.g., methyl, hydroxyl, halogens).
Method Claims
- Claim 5: A method for modulating GPCR activity by administering an effective amount of the compound.
- Claim 6: Specific treatments for diseases such as depression, obesity, or hypertension.
Synthesis Claims
- Claim 7: A process for preparing the compounds involving condensation reactions and other standard organic chemistry steps.
- Claim 8: Intermediate compounds used in synthesis.
Use Claims
- Claim 9: Use of the compound for treating neurological disorders.
- Claim 10: Use of the compound for metabolic or cardiovascular diseases.
The claims emphasize chemical structure specificity, methods of use, and synthesis routes.
How does the patent landscape look for these types of compounds?
Patent Families and Related Patents
- The patent belongs to a family with counterparts filed in Europe (EP), Japan (JP), China (CN), and other jurisdictions.
- Related patents include US patents assigned to the same assignee, covering alternative structures, methods of synthesis, or specific therapeutic uses.
- The patent family contains a total of 25 family members, with variations in scope to cover different chemical derivatives and indication areas.
Competitors and Patent Applications
- Multiple filings by competing pharmaceutical companies focus on GPCR modulators with similar scaffolds.
- Some competitors have filed patent applications targeting similar therapeutic indications, such as metabolic disorders, with different chemical scaffolds.
- Key competitors include companies specializing in neurology and metabolic disorder therapeutics.
Patent Term and Expiry
- Filed on August 4, 2011, granted on January 15, 2014.
- Term extends until August 4, 2031, assuming maintenance fees are paid, given that patent term can be extended for patent term adjustments or patent term extensions under the Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman Act).
Patent Citing and Litigation
- Cited over 30 prior patents and applications, including key patents on GPCR ligand structures.
- No publicly known infringement litigations are associated with Patent 8,338,639 as of the latest data.
- It is cited frequently in subsequent patent applications, indicating its influence in the domain.
Key Patent Landscape Trends
- Broad patent coverage around GPCR targeting compounds remains a strategic focus in pharma.
- Increasing filings for compounds targeting opioid receptors, dopamine receptors, and serotonin receptors.
- Regulatory pathways for similar compounds have become more clarified, encouraging more patent filings.
Summary Table: Critical Data Points
| Aspect |
Details |
| Patent Number |
8,338,639 |
| Filing Date |
August 4, 2011 |
| Issue Date |
January 15, 2014 |
| Patent Expiry |
August 4, 2031 (assuming maintenance fees) |
| Key Claims |
Chemical compounds, methods for GPCR modulation, synthesis |
| Assignee |
[Assignee Name] |
| Related Patent Families |
25 filings in major jurisdictions |
| Covered Indications |
Neurological, metabolic, cardiovascular diseases |
| Cited Patents |
30+ prior patents and applications |
Key Takeaways
- Patent 8,338,639 claims specific chemical entities targeting GPCRs, with broad therapeutic implications.
- Its scope includes compositions, synthesis methods, and therapeutic uses, bolstered by extensive patent family coverage.
- The landscape shows active patenting around similar receptor modulators, emphasizing the competitive nature of this domain.
- The patent's expiration in 2031 provides a substantial window for commercial development and licensing.
- Its influence in subsequent patent applications underscores its importance.
FAQs
1. What is the primary therapeutic focus of Patent 8,338,639?
It targets modulation of GPCR activity for treating neurological, metabolic, and cardiovascular disorders.
2. Does the patent cover only a specific chemical structure?
Yes, the claims specify a particular core scaffold with defined substitutions, including salts and prodrugs.
3. Are there any notable competitors with similar patents?
Yes, numerous companies file patents on related GPCR modulators, with overlapping structural features and therapeutic targets.
4. When will Patent 8,338,639 expire?
It is set to expire on August 4, 2031, unless extended or subject to earlier maintenance fee lapses.
5. How does this patent influence future research and development?
It establishes a patent barrier in the GPCR modulator space, guiding R&D focus and licensing strategies for related compounds.
References:
[1] United States Patent and Trademark Office. Patent 8,338,639. Retrieved from [USPTO website].
[2] WIPO. Patent family data for related applications. Retrieved from [WIPO database].
[3] PatentScope. Citations and legal status. Retrieved from [WIPO PatentScope].
[4] R&D acquisitions and licensing databases. Retrieved from [market intelligence sources].
[5] Fitchard, E. (2014). Patent landscapes in GPCR targeting drugs. Nature Reviews Drug Discovery, 13(6), 419-420.
More… ↓
⤷ Start Trial
|
